Skip to main content

Table 2 Baseline Demography of the Patient Population

From: An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents

Median age, years [range] 61 [29–87]
  No. of patients (%)
Sex  
 Female 27 (14)
 Male 171 (86)
Primary tumor site  
 Oral cavity 54 (27)
 Oropharynx 55 (28)
 Hypopharynx 47 (24)
 Larynx 21 (11)
 Other* 21 (11)
Tumor stage at initial diagnosis  
 I 11 (6)
 II 21 (11)
 III 23 (12)
 IVa 106 (54)
 IVb 16 (8)
 IVc 13 (7)
 Unknown 8 (4)
Initial treatment  
 Neoadjuvant platinum based chemotherapy 52 (26)
 With Fluorouracil 43 (22)
 With Taxanes 41 (21)
 Surgery 142 (72)
 Radiotherapy 168 (85)
 Alone 73 (37)
 With platinum 74 (37)
 With cetuximab 20 (10)
 With taxanes 1 (1)
Pattern of disease  
 Primary metastatic 13 (7)
 Primary locally advanced (palliative treatment) 8 (4)
 Relapse 177 (89)
  Local only 126 (63)
  Metastatic +/- local 51 (26)
Eligibility for inclusion in a clinical trial
Yes 131 (66)
No 67 (34)
PS ≥ 2 53 (27)
Relapse after initial therapy ≤ 6 months 27 (14)
Other concomitant malignancy 3 (2)
Major comorbidity 3 (2)
PS at onset of palliative chemotherapy
 0 28 (14)
 1 117 (59)
 ≥ 2 53 (27)
  1. *Four nasopharynx, 12 sinus tumor, 5 primitive adenopathies.
  2. PS = Perormans Status.